详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

Different serum levels of IgG and complements and recurrence rates in IgG4-positive and negative lacrimal gland benign lymphoepithelial lesion

2| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China

出处：

DOI：

ISSN：

关键词： benign lymphoepithelial lesion lacrimal gland IgG4 complement prognosis

摘要：

To analyze the differences in immune indicators and prognosis between IgG4-positive and negative lacrimal gland benign lymphoepithelial lesion (LGBLEL).This was a single-center retrospective clinical study including 105 cases of IgG4-positive LGBLEL and 41 cases of IgG4-negative LGBLEL. Basic information, related indicators of peripheral venous blood samples using immunoscattering turbidimetry, treatment (partial surgical excision and glucocorticoid therapy) and prognosis (recurrence and death) were collected. Survival curves for recurrence were created using the Kaplan-Meier analysis. Univariate analysis and multivariate regression analysis were used to analyze prognostic factors.The mean age was 50.10±14.23y and 44.76±11.43y (P=0.033) in IgG4-positive and negative group respectively. The serum C3 and C4 was lower in IgG4-positive group (P=0.005, P=0.002), while the serum IgG and IgG2 was higher in IgG4-positive group (P=0.000 and P=0.008). Twenty-one cases had recurrence in IgG4-positive group and 3 cases recurrence in IgG4-negative group. The 5-year recurrence-free cumulative percentages of IgG4-positive group was 81.85%, and 83.46% in the IgG-negative group (P=0.216). The history of preoperative glucocorticoid therapy, serum C4, IgG1 and IgG2 were the factors affecting recurrence in IgG4-positive group, while serum C4, and IgG1 were the factors affecting recurrence of LGBLEL.Serum C4 and IgG1 are the factors affecting recurrence of LGBLEL, while the IgG4 does not affect recurrence of LGBLEL.International Journal of Ophthalmology Press.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 3 区医学

小类 | 3 区眼科学

最新[2023]版：

大类 | 4 区医学

小类 | 4 区眼科学

JCR分区：

出版当年[2021]版：

Q4 OPHTHALMOLOGY

最新[2023]版：

Q2 OPHTHALMOLOGY

影响因子： 1.9 最新[2023版] 1.8 最新五年平均 1.645 出版当年[2021版] 1.934 出版当年五年平均 1.779 出版前一年[2020版] 1.4 出版后一年[2022版]

第一作者：

第一作者机构： [1]Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China

通讯作者：

通讯机构： [1]Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China [*1]Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Macrophage migration inhibitory factor contributes to the pathogenesis of benign lymphoepithelial lesion of the lacrimal gland [2]免疫组织化学检测cd3d、cd4、lck、il-7r在泪腺良性淋巴上皮病变组织的表达及临床意义 [3]Association of the macrophage migration inhibitory factor promoter polymorphisms with benign lymphoepithelial lesion of lacrimal gland [4]Association of the macrophage migration inhibitory factor promoter polymorphisms with benign lymphoepithelial lesion of lacrimal gland [5]Evaluation of the Efficacy of Immune and Inflammatory Markers in the Diagnosis of Lacrimal-Gland Benign Lymphoepithelial Lesion [6]Clinical Research on Benign Lymphoepithelial Lesions of Lacrimal Gland in 20 Chinese Patients [7]良性淋巴上皮病变的研究进展 [8]Association of TCR-signaling pathway with the development of lacrimal gland benign lymphoepithelial lesions [9]泪腺良性淋巴上皮病变免疫组织化学研究 [10]igg亚型与泪腺良性淋巴上皮病变发病关系的研究